Updated Price Disclosure Guidelines
Tuesday, 26 November, 2013
An updated version of the聽Price Disclosure Arrangements Procedural and Operational Guidelines for Expanded and Accelerated Price Disclosure聽has been published.
The updated Guidelines reflect changes made to the聽National Health (Pharmaceutical聽 Benefits) Regulations 1960聽in April 2013. According to the Department of Health website, those Regulation changes were made following December 2012 litigation concerning inclusion of de-listed brands in price disclosure calculations.聽 The Guidelines also provide more information about a number of other matters, including:
- how to disclose data when the commercial responsibility for a brand passes before the legally responsible person has been changed;
- calculating new premiums for price disclosure reductions;
- how price disclosure reductions are applied to new brands listing after the end of a data collection period and before the reduction day;
and
- how reduced prices are adjusted to take account of any change in pricing quantity for brands of a pharmaceutical item between the end of the data collection period and the reduction day
Find out more at聽
Could this strategy mark a turning point in the HIV-cure search?
A team of Australian researchers have repurposed the same mRNA delivery system used in COVID-19...
Key concerns this Sarcoma Awareness Month
July is Sarcoma Awareness Month, and the Australia and New Zealand Sarcoma Association has raised...
Queensland gains private hospital surgery for lymphoedema
Greenslopes Private 黑料吃瓜群网 in Brisbane now offers advanced microsurgery for lymphoedema,...
